Next-generation sequencing has emerged as a valuable tool for generating patient-specific genetic information for clinical diagnostics and optimal selection of targeted therapies. The heterogeneous somatic mutational landscape in cancer makes NGS technologies particularly appealing due to their ability to accurately and simultaneously detect multiple mutations across many genes. Accordingly, oncologists are increasingly recognizing the importance of mutation assessment prior to initiating therapy with targeted therapeutic agents. Issues that must be considered with NGS include technological limitations and opportunities, bioinformatics, test validation requirements, and reporting complexities. Participants will better understand and assess current clinical NGS testing modalities, including the necessary steps required for selecting a NGS assay. The presentation will specifically emphasize the utility of NGS testing in precision oncology with illustrative case examples.
1. Discuss the basic concepts of next-generation sequencing
2. Define the complexities of detecting somatic mutations using tumor-derived DNA
3. Describe the advantages and limitations of clinical NGS for precision oncology